Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/4598

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/4598

Title:	Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant
Authors:	Li, Z.;Ding, Q.;Li, Y.;Miller, S. A.;Abbruzzese, J. L.;Mien-Chie Hung
Date:	2006-03
Issue Date:	2009-11-27 05:57:00 (UTC+0)
Publisher:	Asia University
Abstract:	Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a pancreatic cancer specific promoter (PCSP) is one approach for pancreatic cancer gene therapy. We have modified the promoter of cholecystokinin type A receptor (CCKAR), named CCK/Mpd, which possesses a relatively high activity in pancreatic cancer cells as compared with normal cells. The CCK/Mpd promoter-driven luciferase exhibits a better tumor specific tissue distribution than the CMV promoter-driven luciferase when systemically administered in vivo. Notably, we demonstrate a treatment efficacy by using CCK/Mpd-Bik-DD/liposome in a nude mice xenograft model, suggesting the feasibility of PCSP-based gene therapy in pancreatic cancer treatment.
Relation:	CANCER LETTERS 236(1):58-63
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Description	Size	Format
		0Kb	Unknown	684	View/Open
310904400-4598.doc		30Kb	Microsoft Word	459	View/Open